Search results
Found 2794 matches for
Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.
Emma Plested
Emma Plested - Programme and Regulatory Affairs Director (UK)
Daniel O'Connor
BSc AFHEA MSc DPhil (OXON) Daniel O'Connor - Associate Professor | Head of Bioinformatics
Yama G.Farooq
BCA Computer Application , MSc in Information Technology and Software Engineering Yama G.Farooq - Programming and Data Management Director
Stephane Paulus
MD, DTM&H, FRCPCH Stephane Paulus - Consultant in Paediatric Infectious Diseases